$DWTX
Dogwood Therapeutics, Inc.

2024 Q4 Form 10-Q Financial Statement

#000155837024014957 Filed on November 08, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development $535.2K
YoY Change 43.01%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $2.301M
YoY Change 80.58%
Operating Profit -$2.301M
YoY Change 80.58%
Interest Expense $20.49K
YoY Change -47.76%
% of Operating Profit
Other Income/Expense, Net $20.49K
YoY Change -47.75%
Pretax Income -$2.281M
YoY Change 84.66%
Income Tax
% Of Pretax Income
Net Earnings -$2.281M
YoY Change 84.66%
Net Earnings / Revenue
Basic Earnings Per Share -$2.05
Diluted Earnings Per Share -$2.05
COMMON SHARES
Basic Shares Outstanding 1.332M 27.76M
Diluted Shares Outstanding 1.110M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $2.000M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $2.283M
YoY Change -56.5%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $2.283M
Total Long-Term Assets $0.00
Total Assets $2.283M
YoY Change -56.5%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $455.0K
YoY Change 121.53%
Accrued Expenses $878.9K
YoY Change 211.9%
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.334M
YoY Change 173.8%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.334M
Total Long-Term Liabilities
Total Liabilities $1.334M
YoY Change 173.8%
SHAREHOLDERS EQUITY
Retained Earnings -$66.09M
YoY Change 9.48%
Common Stock $111.00
YoY Change -94.24%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $949.4K
YoY Change
Total Liabilities & Shareholders Equity $2.283M
YoY Change -56.5%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$2.281M
YoY Change 84.66%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash
YoY Change
FREE CASH FLOW
Cash From Operating Activities
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001818844
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39811
dei Entity Registrant Name
EntityRegistrantName
Dogwood Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-4314201
dei Entity Address Address Line1
EntityAddressAddressLine1
44 Milton Avenue
dei Entity Address City Or Town
EntityAddressCityOrTown
Alpharetta
dei Entity Address State Or Province
EntityAddressStateOrProvince
GA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
30009
dei City Area Code
CityAreaCode
866
dei Local Phone Number
LocalPhoneNumber
620-8655
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
DWTX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1332178
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2039819
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3316946
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
243430
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
848496
CY2024Q3 us-gaap Assets Current
AssetsCurrent
2283249
CY2023Q4 us-gaap Assets Current
AssetsCurrent
4165442
CY2024Q3 us-gaap Assets
Assets
2283249
CY2023Q4 us-gaap Assets
Assets
4165442
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
454962
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
111913
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
878856
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
246635
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1333818
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
358548
CY2024Q3 us-gaap Liabilities
Liabilities
1333818
CY2023Q4 us-gaap Liabilities
Liabilities
358548
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
43000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
43000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1118035
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1110317
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
778035
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
770317
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
111
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
77
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
67339522
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
65575167
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-66091074
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-61469222
CY2024Q3 us-gaap Stockholders Equity Before Treasury Stock
StockholdersEquityBeforeTreasuryStock
1248559
CY2023Q4 us-gaap Stockholders Equity Before Treasury Stock
StockholdersEquityBeforeTreasuryStock
4106022
CY2024Q3 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
7718
CY2023Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
7718
CY2024Q3 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
299128
CY2023Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
299128
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
949431
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
3806894
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2283249
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4165442
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
535162
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
374200
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1214964
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1429757
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1766010
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
900089
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3470133
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2879036
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
2301172
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
1274289
us-gaap Operating Expenses
OperatingExpenses
4685097
us-gaap Operating Expenses
OperatingExpenses
4308793
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2301172
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1274289
us-gaap Operating Income Loss
OperatingIncomeLoss
-4685097
us-gaap Operating Income Loss
OperatingIncomeLoss
-4308793
CY2024Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
20488
CY2023Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
39215
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
63245
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
115951
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
20488
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
39215
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
63245
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
115951
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2280684
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1235074
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4621852
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4192842
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-2280684
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1235074
us-gaap Net Income Loss
NetIncomeLoss
-4621852
us-gaap Net Income Loss
NetIncomeLoss
-4192842
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.05
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.05
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.62
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.62
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.95
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.95
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.63
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.63
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1110317
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1110317
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
763750
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
763750
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
932872
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
932872
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
744586
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
744586
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
3806894
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
138969
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-1291335
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
2654528
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1382170
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
148948
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-1049833
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
3135813
CY2024Q3 us-gaap Partners Capital Account Unit Based Compensation
PartnersCapitalAccountUnitBasedCompensation
94302
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-2280684
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
949431
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
7326494
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
161697
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-1516864
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
5971327
CY2023Q2 dwtx Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
292255
CY2023Q2 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
292255
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
161664
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1440904
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
4692087
CY2023Q3 dwtx Stock Issued During Period Value Under Sales Agreement
StockIssuedDuringPeriodValueUnderSalesAgreement
1156443
CY2023Q3 dwtx Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
6874
CY2023Q3 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
6874
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
148305
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1235074
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
4761761
us-gaap Profit Loss
ProfitLoss
-4621852
us-gaap Profit Loss
ProfitLoss
-4192842
us-gaap Share Based Compensation
ShareBasedCompensation
382219
us-gaap Share Based Compensation
ShareBasedCompensation
471666
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-605066
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-875976
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
343049
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-367795
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
632221
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-188323
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2659297
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3401318
dwtx Proceeds From Public Offering Of Common Stock Net Of Offering Costs
ProceedsFromPublicOfferingOfCommonStockNetOfOfferingCosts
1382170
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1156443
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1382170
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1156443
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-1277127
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-2244875
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3316946
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7030992
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2039819
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4786117
dwtx Non Cash Adjustments To Equity Warrants Exercised
NonCashAdjustmentsToEquityWarrantsExercised
299128
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-2280684
us-gaap Net Income Loss
NetIncomeLoss
-4621852
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1235074
us-gaap Net Income Loss
NetIncomeLoss
-4192842
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2659297
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3401318
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-66091074
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2000000.0
CY2023Q4 dwtx Stock Price Per Share Number Of Days Below Required Price
StockPricePerShareNumberOfDaysBelowRequiredPrice
P30D
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 dwtx Stock Minimum Price Per Share
StockMinimumPricePerShare
1.00
CY2023Q4 dwtx Stock Price Per Share Number Of Days To Remedy
StockPricePerShareNumberOfDaysToRemedy
P180D
CY2023Q4 dwtx Stock Minimum Price Per Share
StockMinimumPricePerShare
1.00
CY2023Q4 dwtx Stock Price Per Share Number Of Days Price Must Be Maintained
StockPricePerShareNumberOfDaysPriceMustBeMaintained
P10D
CY2024Q2 dwtx Stock Minimum Price Per Share
StockMinimumPricePerShare
1.00
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27950888
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1118035
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27757937
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1110317
CY2023 dwtx Adjustments To Additional Paid In Capital Reverse Stock Split
AdjustmentsToAdditionalPaidInCapitalReverseStockSplit
1867
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The preparation of these financial statements and accompanying notes in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The Company's significant estimates and assumptions include estimated work performed but not yet billed by contract manufacturers, engineers and research organizations, the valuation of equity and stock-based related instruments, and the valuation allowance related to deferred taxes. Some of these judgments can be subjective and complex, and, consequently, actual results could differ from those estimates. Although the Company believes that its estimates and assumptions are reasonable, they are based upon information </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">available at the time the estimates and assumptions were made. Actual results could differ from those estimates.</p>
CY2024Q3 us-gaap Prepaid Insurance
PrepaidInsurance
171708
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
702352
CY2024Q3 dwtx Prepaid Clinical Research Costs
PrepaidClinicalResearchCosts
11144
CY2023Q4 dwtx Prepaid Clinical Research Costs
PrepaidClinicalResearchCosts
133819
CY2024Q3 dwtx Prepaid Accounting Fees
PrepaidAccountingFees
31975
CY2024Q3 dwtx Prepaid Services
PrepaidServices
7763
CY2023Q4 dwtx Prepaid Services
PrepaidServices
8766
CY2024Q3 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
20840
CY2023Q4 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
3559
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
243430
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
848496
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
627451
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
27550
CY2024Q3 dwtx Accrued Interest On Preferred Members Interest
AccruedInterestOnPreferredMembersInterest
188085
CY2023Q4 dwtx Accrued Interest On Preferred Members Interest
AccruedInterestOnPreferredMembersInterest
188085
CY2024Q3 us-gaap Accrued Vacation Current
AccruedVacationCurrent
49370
CY2024Q3 dwtx Accrued Director Fees Current
AccruedDirectorFeesCurrent
13950
CY2023Q4 dwtx Accrued Director Fees Current
AccruedDirectorFeesCurrent
31000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
878856
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
246635
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
43000000
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
6900
CY2021Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
312.50
CY2021Q4 dwtx Warrants Exercisable Percentage
WarrantsExercisablePercentage
1
CY2022Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
20000
CY2022Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
15.625
CY2023Q1 dwtx Warrants Exercisable Percentage
WarrantsExercisablePercentage
1
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
7755
CY2023Q4 dwtx Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
279.77
CY2023 dwtx Class Of Warrant Or Right Remaining Term
ClassOfWarrantOrRightRemainingTerm
P2Y1M28D
CY2024Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
7755
CY2024Q3 dwtx Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
279.77
dwtx Class Of Warrant Or Right Remaining Term
ClassOfWarrantOrRightRemainingTerm
P1Y4M24D
dwtx Class Of Warrant Or Right Exercisable
ClassOfWarrantOrRightExercisable
7755
dwtx Class Of Warrant Or Right Exercisable Weighted Average Exercise Price
ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice
279.77
dwtx Class Of Warrant Or Right Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm
P1Y4M24D
CY2024Q3 dwtx Aggregate Intrinsic Value Of Warrants Outstanding
AggregateIntrinsicValueOfWarrantsOutstanding
0
CY2024Q4 dwtx Number Of Contingent Value Rights Issuable For Each Common Share
NumberOfContingentValueRightsIssuableForEachCommonShare
1
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1110317
us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
1033000
CY2024Q3 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
1033000
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001558370-24-014957-index-headers.html Edgar Link pending
0001558370-24-014957-index.html Edgar Link pending
0001558370-24-014957.txt Edgar Link pending
0001558370-24-014957-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
viri-20240930.xsd Edgar Link pending
viri-20240930x10q.htm Edgar Link pending
viri-20240930x10q006.jpg Edgar Link pending
viri-20240930xex10d3.htm Edgar Link pending
viri-20240930xex10d4.htm Edgar Link pending
viri-20240930xex10d5.htm Edgar Link pending
viri-20240930xex10d5002.jpg Edgar Link pending
viri-20240930xex10d6.htm Edgar Link pending
viri-20240930xex31d1.htm Edgar Link pending
viri-20240930xex31d2.htm Edgar Link pending
viri-20240930xex32d1.htm Edgar Link pending
viri-20240930xex32d2.htm Edgar Link pending
viri-20240930_cal.xml Edgar Link unprocessable
viri-20240930_def.xml Edgar Link unprocessable
viri-20240930_lab.xml Edgar Link unprocessable
viri-20240930x10q_htm.xml Edgar Link completed
viri-20240930_pre.xml Edgar Link unprocessable